Datasheet is currently unavailable. Try again or CONTACT US
CIITA Antibody
Rabbit Polyclonal
8 References
100-401-249
100 µL
Liquid (sterile filtered)
WB, ChIP, IP
Human
Rabbit
Shipping info:
$50.00 to US & $70.00 to Canada for most products. Final costs are calculated at checkout.
Product Details
Anti-CIITA aa 1-333 (RABBIT) Antibody - 100-401-249
rabbit anti-CIITA Antibody, MHC class II transactivator, CIITA, MHC2TA
Rabbit
Polyclonal
Antiserum
Target Details
CIITA - View All CIITA Products
Human
Recombinant Protein
The immunogen used for this study was a bacterially produced recombinant FLAG-CIITA corresponding to amino acids 1 through 333 of the human protein.
Anti-CIITA antibody was prepared from monospecific antiserum by delipidation and defibrination.
Application Details
WB
ChIP, IP
- View References
Anti-CIITA antibody has been tested in western blot. For immunoblotting a 1:500 dilution is recommended. Researchers should determine optimal titers for other applications.
Formulation
90 mg/mL by Refractometry
None
0.01% (w/v) Sodium Azide
None
Shipping & Handling
Dry Ice
Store vial at -20° C prior to opening. Aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
Expiration date is one (1) year from date of receipt.
Anti-CIITA antibody detects CIITA. The transactivator CIITA regulates basal and interferon-induced expression of Major Histocompatibility Complex class II genes. CIITA restores expression of all MHC class II gene expression in mutant cells and corrects regulatory defects of MHC class II genes. Antibodies to this transactivator are useful in the study of diseases of pathological MHC class II expression. Antigen can be obtained from Raji cell lysates. Typically levels of CIITA expression are too low to detect endogenous levels of protein expression. Transiently transfected cells are usually employed to study this transcription factor.
Su C et al. (2021). EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes. PLoS Pathog.
Applications
ChIP
Majumder P. et al. (2021). The Murine MHC Class II Super Enhancer IA/IE-SE Contains a Functionally Redundant CTCF-Binding Component and a Novel Element Critical for Maximal Expression. J Immunol.
Applications
Undefined
Majumder P. et al. (2020). A super enhancer controls expression and chromatin architecture within the MHC class II locus. J Exp Med
Applications
ChIP
Scharer et al. (2015). Genome-wide CIITA-binding profile identifies sequence preferences that dictate function versus recruitment. Nucleic Acids Research
Applications
ChIP
Uetani K et al. (2008). Influenza A virus abrogates IFN-c response in respiratory epithelial cells by disruption of the Jak/Stat pathway. Eur J Immunol.
Applications
IP, Co-IP
Koues OI et al. (2008). Regulation of Acetylation at the Major Histocompatibility Complex Class II Proximal Promoter by the 19S Proteasomal ATPase Sug1. Mol Cell Biol.
Applications
ChIP
Kohoutek J et al. (2006). Hexim1 sequesters positive transcription elongation factor b from the class II transactivator on MHC class II promoters. Proc Natl Acad Sci USA.
Applications
WB, IB, PCA
Kretsovali A et al. (2001). Self-association of Class II Transactivator Correlates with Its Intracellular Localization and Transactivation. J Biol Chem.
Applications
WB, IB, PCA
This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.